Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Tretinoin for Myelodysplastic Syndromes
NCT00382200Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2006
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin in myelodysplastic syndrome (MDS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities up to 1 year, Maximum Tolerated Dose of Tretinoin When Administered With Decitabine up to 1 year and 2 more. Started Jul 2006; status: completed.
02
Drugs
tretinoin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00382200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382200.